Structure-based virtual screening for novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase and their experimental evaluation.

A public compound library with 260,000 compounds was screened virtually by computational docking for novel inhibitors of the transmembrane enzyme sarco/endoplasmic reticulum calcium ATPase (SERCA). Docking was performed with the program GOLD in conjunction with a high resolution X-ray crystal structure of SERCA. Compounds that were predicted to be active were tested in bioassays. Nineteen novel compounds were discovered that were capable of inhibiting the ATP hydrolysis activity of SERCA at concentrations below 50 microM. Crucial enzyme/inhibitor interactions were identified by analyzing the docking-predicted binding poses of active compounds. Like other SERCA inhibitors, the newly discovered compounds are of considerable medicinal interest because of their potential for cancer chemotherapy.

[1]  B. Maigret,et al.  Discovering new inhibitors of bacterial glucosamine-6P synthase (GlmS) by docking simulations. , 2007, Bioorganic & medicinal chemistry letters.

[2]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[3]  G. Inesi,et al.  Interference with Phosphoenzyme Isomerization and Inhibition of the Sarco-endoplasmic Reticulum Ca2+ ATPase by 1,3-Dibromo-2,4,6-tris(methylisothiouronium) Benzene* , 2005, Journal of Biological Chemistry.

[4]  S. Christensen,et al.  A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. , 1998, Trends in pharmacological sciences.

[5]  H. Yoo,et al.  Comparison of three tetramic acids and their ability to alter membrane function in cultured skeletal muscle cells and sarcoplasmic reticulum vesicles. , 1992, Toxicology and applied pharmacology.

[6]  K. Moncoq,et al.  The Molecular Basis for Cyclopiazonic Acid Inhibition of the Sarcoplasmic Reticulum Calcium Pump* , 2007, Journal of Biological Chemistry.

[7]  S. Christensen,et al.  Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. , 2006, Bioorganic & medicinal chemistry.

[8]  F. Michelangeli,et al.  Inhibition of the SERCA Ca2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. , 2001, European journal of biochemistry.

[9]  S. Orrenius,et al.  2,5‐Di(tert‐butyl)‐1,4‐benzohydroquinone — a novel inhibitor of liver microsomal Ca2+ sequestration , 1987, FEBS letters.

[10]  Norbert,et al.  Cyclopiazonic acid is a specific inhibitor of the Ca2+-ATPase of sarcoplasmic reticulum. , 1989, The Journal of biological chemistry.

[11]  S. Christensen,et al.  Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. , 2001, Journal of medicinal chemistry.

[12]  S. Meltzer,et al.  Thapsigargin resistance in human prostate cancer cells , 2006, Cancer.

[13]  D. Maclennan Purification and properties of an adenosine triphosphatase from sarcoplasmic reticulum. , 1970, The Journal of biological chemistry.

[14]  S. Paula,et al.  Molecular determinants of sarco/endoplasmic reticulum calcium ATPase inhibition by hydroquinone‐based compounds , 2008, Proteins.

[15]  Daniel Vitt,et al.  Virtual high-throughput in silico screening , 2003 .

[16]  S. Orlowski,et al.  Mechanism of inhibition of the (Ca2(+)-Mg2+)-ATPase by nonylphenol. , 1990, Biochemistry.

[17]  R. Guidelli,et al.  Clotrimazole Inhibits the Ca2+-ATPase (SERCA) by Interfering with Ca2+ Binding and Favoring the E2 Conformation* , 2006, Journal of Biological Chemistry.

[18]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[19]  Y. Sugita,et al.  Structural role of countertransport revealed in Ca(2+) pump crystal structure in the absence of Ca(2+). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[21]  Ruth Nussinov,et al.  Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.

[23]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[24]  S. Paula,et al.  Molecular determinants of thapsigargin binding by SERCA Ca2+‐ATPase: A computational docking study , 2004, Proteins.

[25]  Mitchell A. Avery,et al.  Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits , 2008, Bioorganic & Medicinal Chemistry.

[26]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[27]  S. P. Andrews,et al.  Total synthesis of thapsigargin, a potent SERCA pump inhibitor. , 2007, Organic letters.

[28]  J. Møller,et al.  Structural organization, ion transport, and energy transduction of P-type ATPases. , 1996, Biochimica et biophysica acta.

[29]  G. Inesi,et al.  Studies of Ca2+ ATPase (SERCA) Inhibition , 2005, Journal of bioenergetics and biomembranes.

[30]  Hiromi Nomura,et al.  Structural changes in the calcium pump accompanying the dissociation of calcium , 2002, Nature.

[31]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[32]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[33]  G. Booker,et al.  In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand. , 2008, Bioorganic & medicinal chemistry letters.

[34]  Anthony G. Lee,et al.  Binding of sesquiterpene lactone inhibitors to the Ca(2+)-ATPase. , 1995, The Biochemical journal.

[35]  G. Appendino,et al.  SERCA-inhibiting activity of C-19 terpenolides from Thapsia garganica and their possible biogenesis. , 2005, Journal of natural products.

[36]  S. Christensen,et al.  Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. , 1999, Bioorganic & medicinal chemistry.

[37]  S. Christensen,et al.  The Potencies of Thapsigargin and Analogues as Activators of Rat Peritoneal Mast Cells , 1986, Planta Medica.

[38]  J. East,et al.  Interactions of dihydroxybenzenes with the Ca(2+)-ATPase: separate binding sites for dihydroxybenzenes and sesquiterpene lactones. , 1995, Biochemistry.

[39]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[40]  I. Fortea,et al.  Cyclopiazonic acid effect on Ca2+-dependent conformational states of the sarcoplasmic reticulum ATPase. Implication for the enzyme turnover. , 1998, Biochemistry.

[41]  H. Lilja,et al.  Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. , 2003, Journal of the National Cancer Institute.

[42]  Alok Bhattacharya,et al.  Inhibitors of Escherichia coli serine acetyltransferase block proliferation of Entamoeba histolytica trophozoites. , 2008, International journal for parasitology.

[43]  R. J. Cole,et al.  Cyclopiazonic acid inhibition of the Ca2+-transport ATPase in rat skeletal muscle sarcoplasmic reticulum vesicles. , 1988, Biochemical pharmacology.

[44]  F. Soler,et al.  On the Inhibition Mechanism of Sarcoplasmic or Endoplasmic Reticulum Ca2+-ATPases by Cyclopiazonic Acid* , 1997, The Journal of Biological Chemistry.

[45]  M. Akssira,et al.  Transtaganolides A-D: novel metabolites from Thapsia transtagana. , 2005, Organic letters.

[46]  S. P. Andrews,et al.  Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin. , 2007, Organic & biomolecular chemistry.

[47]  Jeffrey J. Gray,et al.  Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. , 2005, Journal of medicinal chemistry.

[48]  F. Michelangeli,et al.  The Effects of the Phenylalanine 256 to Valine Mutation on the Sensitivity of Sarcoplasmic/Endoplasmic Reticulum Ca2+ ATPase (SERCA) Ca2+ Pump Isoforms 1, 2, and 3 to Thapsigargin and Other Inhibitors* , 2006, Journal of Biological Chemistry.

[49]  N. Narayanan,et al.  Clotrimazole, an Antimycotic Drug, Inhibits the Sarcoplasmic Reticulum Calcium Pump and Contractile Function in Heart Muscle* , 1998, The Journal of Biological Chemistry.

[50]  Takanori Nakamura,et al.  The chymotrypsin‐like activity of human prostate‐specific antigen, γ‐seminoprotein , 1987 .

[51]  S. Christensen,et al.  Synthesis of the thapsigargins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  P. Veldhoven,et al.  Inorganic and organic phosphate measurements in the nanomolar range. , 1987, Analytical biochemistry.

[53]  J. Isaacs,et al.  The SERCA pump as a therapeutic target: Making a “smart bomb” for prostate cancer , 2005, Cancer biology & therapy.